Biotech Movers: Retrophin Inc (RTRX) and Agios Pharmaceuticals Inc (AGIO)
Summer is officially over, and the warm weather volume lull is has come to an end.
Posts Tagged ‘Retrophin Inc (RTRX)’
What Will Retrophin Inc (RTRX) Get For Its Money On A Raptor Pharmaceutical Corp. (RPTP) Deal?
The rumor mill is working hard right now in the biotech space, and the latest word is that Retrophin Inc (NASDAQ:RTRX), the company founded by Martin Shkreli, is pitching to buy...
Kevin Kotler’s Healthcare Fund Broadfin Capital Just Had A Disastrous Q1
Though 2016 hasn't been great for the overall hedge fund industry so far, it is turning out to be an especially terrible year for biotech-focused hedge funds.
Top Biotech Picks of Best-Performing Hedge Fund of 2015
Bloomberg recently came out with its list of best performing hedge funds of 2015 and the fund that managed to beat all its rivals and emerge at the top of the list was biotech...
Healthcare Fund Consonance Capital’s Top Picks For Q3 Following Monster First Half
The healthcare sector has appreciated by more than 14% so far this year, so we decided to take a look at how healthcare funds are gearing their portfolios heading into the second...
Broadfin Capital Discloses New Stake in This Canadian Biotechnology Company
Broadfin Capital, led by Kevin Kotler, has initiated a new position in QLT Inc. (USA) (NASDAQ:QLTI). In a new filing with the U.S.
Amicus Therapeutics, Inc. (FOLD), Neurocrine Biosciences, Inc. (NBIX), and Retrophin Inc (RTRX) among Biotech Guru Joseph Edelman’s Top Healthcare Picks
Biotech Guru Joseph Edelman's Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks.
More Than 60% Returns For These Two Hedgies’ Favorite Health Care Picks
The health care sector has appreciated by nearly 30% over the past year. We decided to take a look at three companies that two health care-focused funds, namely James A.
Kevin Kotler’s Broadfin Capital Reveals New Stake in Dipexium Pharmaceuticals (DPRX)
A new filing with the SEC, Kevin Kotler and his hedge fund Broadfin Capital revealed new stake in Dipexium Pharmaceuticals, Inc (NASDAQ:DPRX).
Kevin Kotler’s Broadfin Capital’s and MELA Sciences (MELA)
A new filing with the SEC revealed, Kevin Kotler and his hedge fund Broadfin Capital revealed a trimmed stake in MELA Sciences, Inc (NASDAQ:MELA).
Recent Changes in SAC Capital Advisors’ Equity Portfolio
Steven Cohen's SAC Capital Advisors cut its exposure to a certain number of positions.
Steven Cohen’s SAC Capital Advisors Boosts Its Stake in DeVry Education Group Inc (DV)
Steven Cohen’s SAC Capital Advisors, has significantly increased its position in DeVry Education Group Inc (NYSE:DV) to over 3.17 million shares from 27,391 shares, held at ...
Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO
Broadfin Capital, led by Kevin Kotler, in a filing with the Securities and Exchange Commission, reported initiating a position in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO).
Steven Cohen Also Initiates Stake in Retrophin Inc (RTRX)
Steven Cohen, in a new filing with the SEC disclosed initiating a stake in Retrophin Inc (NASDAQ:RTRX). According to the filing, Mr.
Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ
Kevin Kotler’s Broadfin Capital has revealed a new stake in Retrophin Inc (NASDAQ:RTRX), which amasses 6.93% of the company’s common stock, it contains 1.61 million shares...
